Drugs / Pegasys(TM)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02233075 | Sep 2014 → Nov 2016 | chronic hepatitis B virus infection | Replicor Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 10
| Date | Issuer | Release |
|---|---|---|
| 2015-06-30 | Replicor Inc. | Results Replicor discloses updated clinical trial data to the Global Virus Hepatitis Summit in Berlin replicor.com ↗
These data demonstrate the continued elimination of serum HDV RNA during combination treatment in all patients. |
| 2015-06-10 | Replicor Inc. | Results Replicor to Present at the Israel Association for the Study of Liver Conference and the Global Virus Hepatitis Summit in Berlin in June replicor.com ↗
The data from the previous three clinical trials, together with the preliminary data from the REP 301 trial, demonstrate that REP 2139 used alone or in combination with Pegasys® or ZADAXIN® or Pegasys® and ETV is safe and well-tolerated. |
| 2015-04-10 | Replicor Inc. | Results Replicor to Present at the 2015 Lancet Viral Hepatitis Conference replicor.com ↗
These clinical trials indicated that REP 2139-Ca appears to significantly increase the 12-month SVR rate achieved compared to existing therapies. |
| 2014-12-01 | Replicor Inc. | Results Replicor a biopharmaceutical company targeting a cure for Chronic Hepatitis B patients will present updated human clinical trial data documenting a 4 to 6 log reduction in s-antigen and a long-term SVR in 80% of patients. replicor.com ↗ |
| 2014-10-07 | Replicor Inc. | Results Replicor to present updated clinical trial data with combination treatment using its HBsAg-release inhibitors in patients with chronic hepatitis B infection at the 10th Annual Meeting of the Oligonucleotide Therapeutics Society. replicor.com ↗
Data presented by Replicor during its presentation at the OTS meeting on Oct 15th will demonstrate 1) the unique ability of Replicor’s NAP compounds to completely suppress HBsAg in the blood 2) the effect of HBsAg clearance on dramatically improving the activity of immunotherapy and 3) when used with a full course of Pegasys™, NAP therapy has resulted in the establishment of long term SVR in 80% of patients. |
| 2013-05-14 | Replicor Inc. | Results Replicor presents clinical efficacy and toxicology results in patients with chronic hepatitis B with short term exposure to immunotherapy after REP 2139-ca induced clearance of serum HBsAg. replicor.com ↗
Efficacy and toxicology results in Replicor’s proof of concept trials from monotherapy exposure to REP 2055 or REP 2139-ca were disclosed on Tuesday May 14th, 2013 at the 15 th annual TIDES meeting held in Boston, U.S.A. |
| 2013-04-26 | Replicor Inc. | Results Replicor presents updated clinical efficacy results in patients with chronic hepatitis B with short term exposure to immunotherapy in combination with REP 2139-ca and new clinical data in patients receiving this combination treatment while currently on entecavir (triple combination therapy). replicor.com ↗
Patients who had cleared HBsAg from their blood with REP 2139-ca monotherapy were subjected to combination treatment with REP 2139-ca and either Pegasys™ or Zadaxin™. |
| 2013-02-27 | Replicor Inc. | Results Replicor updates clinical efficacy results in patients with chronic hepatitis B with short term exposure to immunotherapy in combination with REP 2139 replicor.com ↗
Profound increases in anti-HBV antibodies or immune function were observed in all patients with as few as 6-10 weeks of combination treatment. |
| 2012-11-12 | Replicor Inc. | Results Replicor updates clinical results demonstrating the achievement of therapeutic vaccine-like responses in patients with chronic hepatitis B with short term exposure to immunotherapy in combination with REP 2139 replicor.com ↗
All patients have achieved HBV antibody levels seen in healthy patients after vaccination with a total of 12 weeks of combination treatment and many patients have achieved antibody titers > 1000 mIU / ml. |
| 2012-09-25 | Replicor Inc. | Results Replicor discloses achievement of therapeutic vaccine-like responses in patients with chronic hepatitis B with short term exposure to immunotherapy in combination with REP 2139 replicor.com ↗
Profound increases in anti-HBV antibodies or immune function were observed in all patients with as few as 6-10 weeks of combination treatment. |
All press releases naming this drug 12 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegasys(TM) | “Pegasys(TM) = pegylated interferon alpha-2a” NCT02233075 ↗ |
| Known as | Pegasys(TM) = pegylated interferon alpha-2a | “Pegasys(TM) = pegylated interferon alpha-2a” NCT02233075 ↗ |
| Route | Subcutaneous | “Pegasys(TM) (180 ug QW SC)” NCT02233075 ↗ |